Zomedica Corp. Files 8-K: Board & Compensation Updates
Ticker: ZOMDF · Form: 8-K · Filed: Dec 19, 2024 · CIK: 1684144
| Field | Detail |
|---|---|
| Company | Zomedica Corp. (ZOMDF) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $155M, $67M, $583M, $194M, $350,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
Related Tickers: ZOM
TL;DR
Zomedica filed an 8-K on 12/19/24 covering board changes and compensation. Keep an eye on leadership moves.
AI Summary
Zomedica Corp. filed an 8-K on December 19, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, indicating ongoing corporate governance and financial reporting activities for the company.
Why It Matters
This filing signals potential shifts in Zomedica's leadership and financial strategy, which could impact its future operations and investor relations.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate strategic shifts or internal challenges within a company.
Key Players & Entities
- Zomedica Corp. (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
- 100 Phoenix Drive, Suite 125 Ann Arbor, Michigan 48108 (address) — Principal Executive Office Address
FAQ
What specific changes were made to Zomedica Corp.'s board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' under Item 5.02, but the specific names and details of the changes are not provided in this excerpt.
What are the key details regarding the compensatory arrangements of certain officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' under Item 5.02, but the specific details of these arrangements are not included in the provided text.
What is the primary purpose of this 8-K filing for Zomedica Corp.?
The primary purpose is to report current information regarding significant corporate events, specifically changes in directors/officers and executive compensation, as well as to file financial statements and exhibits.
When was Zomedica Corp. incorporated, and where is its principal executive office located?
Zomedica Corp. was incorporated in Alberta, Canada, and its principal executive office is located at 100 Phoenix Drive, Suite 125, Ann Arbor, Michigan 48108.
What is Zomedica Corp.'s Standard Industrial Classification (SIC) code?
Zomedica Corp.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,113 words · 4 min read · ~4 pages · Grade level 10.7 · Accepted 2024-12-19 16:30:31
Key Financial Figures
- $155M — enure with Healthios, Mr. Jordan raised $155M of private placements, $67M of non-dilu
- $67M — dan raised $155M of private placements, $67M of non-dilutive capital (CPRIT, NIH), c
- $583M — n-dilutive capital (CPRIT, NIH), closed $583M in licensing deals, and secured $194M v
- $194M — d $583M in licensing deals, and secured $194M via public offerings. In connection wi
- $350,000 — reed to pay Mr. Jordan a base salary of $350,000 per annum. At the conclusion of each ca
- $35,000 — also receive a one-time bonus amount of $35,000 upon the completion of his relocation t
Filing Documents
- zom_8k.htm (8-K) — 33KB
- zom_ex101.htm (EX-10.1) — 8KB
- zom_ex991.htm (EX-99.1) — 17KB
- zom_ex101img22.jpg (GRAPHIC) — 301KB
- zom_ex101img24.jpg (GRAPHIC) — 196KB
- zom_ex101img23.jpg (GRAPHIC) — 233KB
- zom_ex101img26.jpg (GRAPHIC) — 32KB
- zom_ex101img21.jpg (GRAPHIC) — 282KB
- zom_ex101img20.jpg (GRAPHIC) — 261KB
- zom_ex101img19.jpg (GRAPHIC) — 274KB
- zom_ex101img18.jpg (GRAPHIC) — 270KB
- zom_ex101img17.jpg (GRAPHIC) — 265KB
- zom_ex101img16.jpg (GRAPHIC) — 309KB
- zom_ex101img15.jpg (GRAPHIC) — 251KB
- zom_ex101img14.jpg (GRAPHIC) — 171KB
- zom_ex101img27.jpg (GRAPHIC) — 40KB
- zom_ex991img2.jpg (GRAPHIC) — 4KB
- zom_ex101img25.jpg (GRAPHIC) — 258KB
- 0001654954-24-015750.txt ( ) — 4520KB
- zom-20241219.xsd (EX-101.SCH) — 6KB
- zom-20241219_lab.xml (EX-101.LAB) — 14KB
- zom-20241219_cal.xml (EX-101.CAL) — 1KB
- zom-20241219_pre.xml (EX-101.PRE) — 9KB
- zom-20241219_def.xml (EX-101.DEF) — 2KB
- zom_8k_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibit No. Description 10.1 Employment Agreement, dated December 18, 2024, between Zomedica Corp., Zomedica Inc. and Scott Jordan 99.1 Press Release, dated December 19, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZOMEDICA CORP. Date: December 19, 2024 By: /s/Karen DeHaan-Fullerton Name: Karen DeHaan-Fullerton Title: General Counsel and Corporate Secretary 4 EXHIBIT INDEX (d) Exhibit No. Description 10.1 Employment Agreement, dated December 18, 2024, between Zomedica Corp., Zomedica Inc. and Scott Jordan 99.1 Press Release, dated December 19, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 5